Regeneron Pharmaceuticals, Inc. $REGN Stock: Intech Investment Management LLC Decreases Stake

Intech Investment Management LLC cut its holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report) by 28.1% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 16,015 shares of the biopharmaceutical company’s stock after selling 6,245 shares during the quarter. Intech Investment Management LLC’s holdings in Regeneron Pharmaceuticals were worth $12,144,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the business. BlackRock Inc. bought a new stake in shares of Regeneron Pharmaceuticals in the 2nd quarter valued at about $5,682,636,000. State Street Corp lifted its position in shares of Regeneron Pharmaceuticals by 3.6% in the 2nd quarter. State Street Corp now owns 4,834,688 shares of the biopharmaceutical company’s stock worth $3,014,621,000 after purchasing an additional 170,210 shares during the period. Bank of America Corp DE lifted its position in shares of Regeneron Pharmaceuticals by 2.8% in the 1st quarter. Bank of America Corp DE now owns 1,189,584 shares of the biopharmaceutical company’s stock worth $919,120,000 after purchasing an additional 32,158 shares during the period. Amundi boosted its stake in shares of Regeneron Pharmaceuticals by 27.5% during the first quarter. Amundi now owns 1,009,798 shares of the biopharmaceutical company’s stock valued at $780,210,000 after purchasing an additional 217,892 shares in the last quarter. Finally, Aberdeen Group plc boosted its stake in shares of Regeneron Pharmaceuticals by 560.7% during the third quarter. Aberdeen Group plc now owns 671,042 shares of the biopharmaceutical company’s stock valued at $508,831,000 after purchasing an additional 569,476 shares in the last quarter. 83.31% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In other news, insider Andrew J. Murphy sold 4,147 shares of the company’s stock in a transaction on Wednesday, October 14th. The stock was sold at an average price of $772.70, for a total transaction of $3,204,386.90. Following the transaction, the insider directly owned 47,833 shares of the company’s stock, valued at approximately $36,960,559.10. This represents a 7.98% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Kathryn Guarini sold 400 shares of the stock in a transaction on Friday, October 30th. The shares were sold at an average price of $900.00, for a total value of $360,000.00. Following the sale, the director owned 603 shares of the company’s stock, valued at approximately $542,700. This represents a 39.88% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 27,028 shares of company stock valued at $25,025,950 over the last quarter. Insiders own 6.97% of the company’s stock.

Regeneron Pharmaceuticals Stock Down 0.3%

NASDAQ:REGN opened at $952.40 on Tuesday. Regeneron Pharmaceuticals, Inc. has a fifty-two week low of $591.52 and a fifty-two week high of $991.73. The stock has a market capitalization of $98.53 billion, a P/E ratio of 21.03, a P/E/G ratio of 1.26 and a beta of 0.10. The company has a debt-to-equity ratio of 0.06, a quick ratio of 2.89 and a current ratio of 3.35. The company’s 50-day simple moving average is $818.67 and its 200-day simple moving average is $748.36.

Regeneron Pharmaceuticals (NASDAQ:REGN – Get Free Report) last posted its quarterly earnings data on Friday, October 30th. The biopharmaceutical company reported $20.07 EPS for the quarter, topping the consensus estimate of $16.51 by $3.56. The firm had revenue of $5.12 billion during the quarter, compared to analyst estimates of $4.58 billion. Regeneron Pharmaceuticals had a net margin of 28.51% and a return on equity of 16.01%. Regeneron Pharmaceuticals’s revenue was up 36.3% on a year-over-year basis. During the same quarter in the previous year, the business posted $11.83 EPS. On average, equities analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 58.26 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Thursday, December 3rd. Shareholders of record on Friday, November 20th will be paid a $0.94 dividend. This represents a $3.76 annualized dividend and a yield of 0.4%. The ex-dividend date is Friday, November 20th. Regeneron Pharmaceuticals’s dividend payout ratio (DPR) is 8.30%.

Wall Street Analyst Weigh In

Several equities analysts recently issued reports on the stock. Bank of America lifted their price objective on shares of Regeneron Pharmaceuticals from $908.00 to $1,030.00 and gave the company a “buy” rating in a report on Monday, November 2nd. HSBC upped their target price on Regeneron Pharmaceuticals from $800.00 to $920.00 and gave the stock a “buy” rating in a report on Thursday, September 10th. The Goldman Sachs Group increased their target price on Regeneron Pharmaceuticals from $965.00 to $972.00 and gave the company a “buy” rating in a research report on Friday, July 31st. Weiss Ratings upgraded Regeneron Pharmaceuticals from a “hold (c)” rating to a “hold (c+)” rating in a report on Monday, November 2nd. Finally, Guggenheim lifted their price target on Regeneron Pharmaceuticals from $1,030.00 to $1,100.00 and gave the company a “buy” rating in a report on Monday, November 2nd. One research analyst has rated the stock with a Strong Buy rating, twenty-one have issued a Buy rating and nine have given a Hold rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $898.97.

Read Our Latest Stock Report on REGN

About Regeneron Pharmaceuticals

(Free Report)

Regeneron Pharmaceuticals, Inc. is a biotechnology company that discovers, develops, manufactures and commercializes medicines for serious diseases. Its research and product portfolio spans areas including eye disease, allergic and inflammatory conditions, cancer, cardiovascular and metabolic disorders, infectious diseases and rare conditions. The company’s medicines include EYLEA for certain eye diseases, Dupixent for inflammatory conditions and Libtayo for cancer. Regeneron also develops and markets treatments with pharmaceutical partners, including Sanofi, and its products reach patients in the United States and international markets through its own operations and collaborations.

See Also

Institutional Ownership by Quarter for Regeneron Pharmaceuticals (NASDAQ:REGN)

Receive News & Ratings for Regeneron Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.